developed immunomagnetic nanoparticles targeting MUC16, which efficiently extract circulating tumor cells (CTCs) in liquid biopsies, leveraging the widespread expression of MUC16 in high-grade serous ovarian cancer to provide an effective targeting technique for ovarian cancer detection (134). This evidence concerns the gene MUC16 and ovarian serous adenocarcinoma.